UCB (OTCMKTS:UCBJF) Shares Gap Down - Time to Sell?

Key Points

• Shares gapped down — UCB opened at $288.76 vs. the prior close of $312.09, was last reported at $300.29 (down ~3.8%) on extremely light volume (11 shares).
• Analysts remain broadly positive with six firms assigning a consensus "Buy" rating, including Wolfe Research, Barclays, Goldman Sachs, Deutsche Bank and Stephens.
• Key technicals and fundamentals: the 50‑day moving average is $311.03 versus the 200‑day at $285.11, with a current ratio of 1.19, quick ratio 0.78 and debt‑to‑equity of 0.33.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $312.09, but opened at $288.76. UCB shares last traded at $300.29, with a volume of 11 shares changing hands.

Analyst Upgrades and Downgrades

UCBJF has been the topic of several research reports. Wolfe Research initiated coverage on UCB in a report on Monday, February 23rd. They set an "outperform" rating on the stock. Barclays restated an "overweight" rating on shares of UCB in a report on Tuesday, January 6th. The Goldman Sachs Group restated a "buy" rating on shares of UCB in a report on Monday, February 16th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of UCB in a research report on Monday, December 8th. Finally, Stephens reaffirmed an "overweight" rating on shares of UCB in a research note on Thursday, January 15th. Six investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy".

UCB Stock Down 3.8%

The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The business has a fifty day moving average price of $311.03 and a 200 day moving average price of $285.11.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB's work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.